WO2015041529A2 - Improved process for the humanization of animal skim milk - Google Patents
Improved process for the humanization of animal skim milk Download PDFInfo
- Publication number
- WO2015041529A2 WO2015041529A2 PCT/NL2014/050643 NL2014050643W WO2015041529A2 WO 2015041529 A2 WO2015041529 A2 WO 2015041529A2 NL 2014050643 W NL2014050643 W NL 2014050643W WO 2015041529 A2 WO2015041529 A2 WO 2015041529A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- originating
- mfr
- ufp
- process according
- protein
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 130
- 230000008569 process Effects 0.000 title claims abstract description 111
- 235000020183 skimmed milk Nutrition 0.000 title claims abstract description 76
- 241001465754 Metazoa Species 0.000 title claims abstract description 51
- 235000013350 formula milk Nutrition 0.000 claims abstract description 71
- 235000016709 nutrition Nutrition 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- 239000000047 product Substances 0.000 claims description 113
- 239000005018 casein Substances 0.000 claims description 75
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 75
- 235000021240 caseins Nutrition 0.000 claims description 75
- 238000000108 ultra-filtration Methods 0.000 claims description 75
- 238000001471 micro-filtration Methods 0.000 claims description 73
- 239000000203 mixture Substances 0.000 claims description 72
- 108010046377 Whey Proteins Proteins 0.000 claims description 70
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 67
- 239000012466 permeate Substances 0.000 claims description 67
- 239000008101 lactose Substances 0.000 claims description 66
- 235000018102 proteins Nutrition 0.000 claims description 65
- 102000004169 proteins and genes Human genes 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 65
- 239000012528 membrane Substances 0.000 claims description 57
- 102000007544 Whey Proteins Human genes 0.000 claims description 56
- 239000012465 retentate Substances 0.000 claims description 54
- 235000021119 whey protein Nutrition 0.000 claims description 52
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 49
- 239000011707 mineral Substances 0.000 claims description 49
- 238000001728 nano-filtration Methods 0.000 claims description 42
- 238000011026 diafiltration Methods 0.000 claims description 37
- 238000001223 reverse osmosis Methods 0.000 claims description 35
- 238000001914 filtration Methods 0.000 claims description 34
- 238000005115 demineralization Methods 0.000 claims description 27
- 230000002328 demineralizing effect Effects 0.000 claims description 26
- 239000004615 ingredient Substances 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000011575 calcium Substances 0.000 claims description 21
- 239000011734 sodium Substances 0.000 claims description 19
- 239000005862 Whey Substances 0.000 claims description 18
- 239000011777 magnesium Substances 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 15
- 239000003925 fat Substances 0.000 claims description 14
- 229910052698 phosphorus Inorganic materials 0.000 claims description 14
- 235000020209 toddler milk formula Nutrition 0.000 claims description 14
- 229910052749 magnesium Inorganic materials 0.000 claims description 13
- 229910052700 potassium Inorganic materials 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 12
- 239000011574 phosphorus Substances 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 11
- 239000011591 potassium Substances 0.000 claims description 11
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 235000013406 prebiotics Nutrition 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 239000000919 ceramic Substances 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000006041 probiotic Substances 0.000 claims description 4
- 235000018291 probiotics Nutrition 0.000 claims description 4
- 235000020218 follow-on milk formula Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000002699 waste material Substances 0.000 abstract description 4
- 102000011632 Caseins Human genes 0.000 description 77
- 108010076119 Caseins Proteins 0.000 description 77
- 150000002500 ions Chemical class 0.000 description 55
- 235000010755 mineral Nutrition 0.000 description 48
- 238000001035 drying Methods 0.000 description 29
- 239000007788 liquid Substances 0.000 description 26
- 239000007787 solid Substances 0.000 description 25
- 239000002956 ash Substances 0.000 description 20
- 238000002156 mixing Methods 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229960005069 calcium Drugs 0.000 description 14
- 238000001704 evaporation Methods 0.000 description 14
- 230000008020 evaporation Effects 0.000 description 14
- 230000009469 supplementation Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 239000012141 concentrate Substances 0.000 description 9
- 235000020256 human milk Nutrition 0.000 description 9
- 210000004251 human milk Anatomy 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000001506 calcium phosphate Substances 0.000 description 8
- 229910000389 calcium phosphate Inorganic materials 0.000 description 8
- 235000011010 calcium phosphates Nutrition 0.000 description 8
- 239000012467 final product Substances 0.000 description 8
- 235000021125 infant nutrition Nutrition 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 235000020244 animal milk Nutrition 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 238000000909 electrodialysis Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 238000009928 pasteurization Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000021247 β-casein Nutrition 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108091008680 RAR-related orphan receptors Proteins 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 235000011116 calcium hydroxide Nutrition 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002036 drum drying Methods 0.000 description 3
- 238000007580 dry-mixing Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000004847 absorption spectroscopy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000009285 membrane fouling Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000010901 surplus milk Substances 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1425—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of whey, e.g. treatment of the UF permeate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1427—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by dialysis, reverse osmosis or hyperfiltration, e.g. for concentrating or desalting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/202—Casein or caseinates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
- A23J3/08—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2210/00—Physical treatment of dairy products
- A23C2210/20—Treatment using membranes, including sterile filtration
- A23C2210/206—Membrane filtration of a permeate obtained by ultrafiltration, nanofiltration or microfiltration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2210/00—Physical treatment of dairy products
- A23C2210/25—Separating and blending
- A23C2210/252—Separating a milk product in at least two fractions followed by treatment of at least one of the fractions and remixing at least part of the two fractions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention relates to the treatment of animal skim milk, which is ideally suited for the preparation of infant formulae, infant formula base products and/or nutritional products suitable for feeding toddlers, as well as to products obtainable by such treatment.
- Human milk is considered the 'golden standard' for infant nutrition. Processing animal milk, for example cow's milk, to more resemble the composition of human milk is known in the art as 'humanizing' animal milk.
- the process of humanizing animal milk involves changing the ratio of caseimwhey proteins as found in animal milk (e.g. approximately 80:20 for cow's milk) to the desired ratio for infant nutrition as found in human milk, for example between 75:25 and 30:70, or usually approximately 40/60, which is the ratio found in human milk in months 0 - 6 post-partem.
- the mineral content of animal milk is typically higher than the content found in human milk.
- humanization of animal milk also involves reducing of the mineral content.
- Preparation of products suitable for use in infant nutrition typically involves blending of various individually purified components in the appropriate ratios, either wet or dry.
- Current manufacturing processes require multiple dairy ingredients from intermediate suppliers, including skim milk or a concentrate thereof, including skim milk powder, demineralised whey or a concentrate thereof, including demineralised whey powder, whey protein concentrates or isolates, normally as powders, and pure grade lactose, typically in powder form, to formulate a nutritionally balanced infant formula.
- WO 96/08155 describes a process for treating skim milk for the manufacture of cheese and milk powders, wherein whey proteins are removed from skim milk by microfiltration (MF) and ultrafiltration (UF). Volume concentration factors of 20 - 100 are employed in the UF step. No recombination of the MF retentate and UF permeate is described for the preparation of infant formulae and no attention is given to the concentration of minerals and trace elements such as phosphorus.
- US 5,503,865 discloses a process for treating skim milk, comprising microfiltration or ultrafiltration. The permeate thereof may be demineralised by for example ion exchange and/or electrodialysis in order to make the skim milk product suitable to be used in infant formulae. No combination of filtration techniques is disclosed.
- WO 2008/127104 discloses the production of whey protein serum comprising residual beta casein by subjecting cow's milk to microfiltration over a membrane with a pore size of 0.3 - 0.5 micrometer at a temperature from 10 - 20 °C, optionally with a further concentration step.
- the enlarged porosity gives rise to undesirably high casein content in the whey stream.
- EP 1133238 describes a process wherein animal milk is subjected to microfiltration through a membrane having a porosity of 0.1 - 0.2 micrometer, after which the MF permeate is demineralised by electrodialysis.
- the mineral content of the electrodialyzed MF permeate is very low, and subsequent fortification with minerals and trace elements is required to obtain an infant formula.
- WO 2009/059266 describes a process for preparing casein from skim milk by microfiltration, using a MF membrane having a porosity of 20 - 200 kDa and a VCF of 5 - 6.
- UF of the MF permeate may be used to separate the whey protein fraction into a- lactalbumin and ⁇ -lactoglobulin.
- WO 2013/068653 describes a process for treating skim milk for the manufacture of infant formula bases, comprising MF of milk and UF of the MF permeate. Volume concentration factors of 2 - 10 are employed in the MF step and of 10 - 80 in the UF step.
- the lactose containing UF permeate is subjected to nanofiltration (NF) and used without further mineral removal steps in the preparation of infant formula bases.
- NF nanofiltration
- Such process would give rise to a final product which has unacceptably high mineral content, in particular too much divalent ions, as those do not permeate the NF membrane. This is reflected in the exemplary infant formulae disclosed in tables 2 - 7 of WO 2013/068563, which all have an ash content of 0.34 wt% or higher, based on final liquid product, which is undesirably high.
- animal skim milk can be humanized by an efficient and cheap process, requiring minimal processing steps and enabling maximal use of the ingredients in animal skim milk.
- the invention concerns a process for the preparation of an infant formula base product, comprising:
- MF microfiltration
- step (b) ultrafiltration (UF) of the MFP originating from step (a) over a membrane having a molecular weight cut-off of at most 25 kDa and operating with a volume concentration factor of 1.5 - 8, resulting in a retentate (UFR) and a permeate (UFP);
- step (c) combining the MFR originating from step (a) and the UFR originating from step (b), whereby a composition having a casein/whey protein weight ratio of 20/80 - 70/30 is obtained.
- the process of the present invention has several advantages over existing methods of producing infant formula base products, e.g. the loss in lactose yield and whey during the processing of skim milk and whey is reduced, for example during conventional demineralization of whey and crystallization of lactose, complications related to fouling of membranes and deposition of protein material are reduced, the use of additions of chemicals is reduced and waste water may be recycled in the process to a large extent.
- the process according to the present invention may be designed as a closed-loop process, in which hardly any waste is formed. As such, the amount of waste and waste streams is greatly reduced compared to the conventional process. In addition, the need for energy consuming drying and demineralization steps is reduced.
- the lactose yield in conventional purification methods for the production of dairy products lies around 83-85%
- the lactose yield can be improved to over 90% in the process of the present invention.
- the yield of casein and whey proteins, as well as the yield of the minerals could be increased to at least 90 wt%, or even above 95 wt%.
- the yield represents the amount of a component present in the incoming skim milk that is included in the final infant formula base products and/or other nutritional compositions for infant nutrition.
- the present process utilizes virtually all nutritional components of the animal skim milk.
- the process according to the invention has a lower environmental impact compared to the conventional process for producing infant formula base products.
- an "infant formula base product” is a liquid or powdered composition, suitable for making infant formulae or other nutritional compositions suitable for feeding infants.
- the present process is for preparing base products for infant formulae, follow-on formulae or growing-up milks, which comprise all or almost all essential ingredients in the required amounts for infant nutrition.
- Compositions wherein one or more of the ingredients of an infant formula is present in too low amounts (i.e. is below target) is also considered an infant formula base product in the context of the present invention.
- on target is meant to indicate that the content of a specific component in a composition is such, that when an infant formula is manufactured from said composition, the content of that particular component is within the regulatory ranges of that component.
- Such legal requirements for infant formulae and infant formula base products are known to the skilled person, and are obtainable from for example the EFSA and/or the FDA (e.g. EU directive 91/321/EEC, or EU directive 2006/141/EC, US Food and Drug Administration 21 CFR Ch 1 part 107).
- MF microfiltration
- UF ultrafiltration
- NF nanofiltration
- RO reverse osmosis
- MF is known in the art to be any type of filtration over a membrane having a porosity of 0.1 - 10 micrometer.
- UF is known in the art to be any type of filtration over a membrane having a porosity of 1 - 100 nanometer or a molecular weight cut-off (MWCO) of approximately 5 kDa - approximately 500 kDa.
- MWCO molecular weight cut-off
- NF is known in the art to be any type of filtration over a membrane having a MWCO below approximately 1000 Da, typically below 150 Da.
- RO is known in the art to be a filtration technique that allows the permeation of solvent molecules only while retaining all solutes.
- Each of these filtration steps may be enhanced with diafiltration (DF) as known in the art.
- DF diafiltration
- These filtration steps partition an incoming liquid stream in a permeate and a retentate, whereby typically certain solutes become concentrated in the retentate, and others may permeate together with the solvent.
- the "volume concentration factor" or "VCF" is the factor at which a liquid composition is concentrated upon filtration, i.e. the total volume of the incoming stream prior to filtration divided by the total volume of the retentate after filtration, irrespective of the total solid content.
- composition can be the composition which is directly obtained by said process step, typically either as permeate or as retentate.
- additional processing steps such as partial evaporation and/or supplementation of additional water or other components, the composition is still regarded to originate from that specific process step.
- the permeate of the MF of step (a) would be partially evaporated prior to it is entered in the UF of step (b)
- the incoming stream of the UF step is regarded to be a MFR originating from step (a).
- the starting material for the present process is animal skim milk, preferably bovine skim milk.
- Animal skim milk i.e. non-human skim milk, preferably from bovine animals, and may be used as such, in diluted or concentrated form, as skim milk concentrate that optionally is diluted or as reconstituted skim milk powder.
- the animal skim milk may be pretreated as known in the art, for example to reduce the bacterial content of the animal skim milk. Suitable methods include heat treatment (e.g. sterilization or pasteurization) or bacterial microfiltration. Such bacterial microfiltration, preferably over a membrane having a porosity of 1.0 - 2.0 micrometer, is employed to remove bacterial contamination of non-heat treated animal skim milk.
- heat treatment e.g. sterilization or pasteurization
- bacterial microfiltration preferably over a membrane having a porosity of 1.0 - 2.0 micrometer, is employed to remove bacterial contamination of non-heat treated animal skim milk.
- animal skim milk is fractioned into two distinct streams, each enriched in a particular protein type; a casein enriched MF retentate (MFR) and a whey protein enriched MF permeate (MFP) are produced.
- MFR casein enriched MF retentate
- MFP whey protein enriched MF permeate
- the MF step (a) is performed over a membrane that enables fractionation of casein and whey proteins.
- a membrane that enables fractionation of casein and whey proteins.
- a membrane has a porosity of 0.10 - 0.35 micrometer.
- a ceramic membrane or a spiral wound (organic) membrane is used.
- the porosity is 0.10 - 0.30 micrometer
- the porosity is 0.10 - 0.35 micrometer, more preferably 0.15 - 0.35 micrometer.
- a ceramic or spiral wound membrane is used with a porosity of 0.15 - 0.25 micrometer, most preferably a spiral wound membrane with a porosity of 0.15 - 0.25 micrometer is used.
- the MF step (a) preferably operates with a volume concentration factor (VCF) of 1.5 - 8, preferably 2 - 5, more preferably 2 - 4, most preferably 2.5 - 3.5.
- the MF step is preferably performed below 75 °C, more preferably from 1 °C - 60 °C, even more preferably from 5 °C - 25 °C, most preferably from 7 °C - 15 °C.
- this permeate is used, preferably after a further process step such as UF, for the manufacture of an infant formula base product, the fraction of ⁇ -casein in the casein component will be increased, which is more reminiscent to human milk.
- the amino acid composition of the infant formula base product more closely resembles the amino acid profile of human milk.
- the chance on bacterial contamination of the animal skim milk treated according to the invention increases, which is undesirable for the preparation of nutritional products for infants.
- microfiltration of step (a) is enhanced with diafiltration (DF).
- Diafiltration may be accomplished by diluting the retentate of the MF at least once with an amount of water, or by diluting the incoming animal skim milk with an amount of water and subjecting the diluted animal skim milk to MF.
- the amount of DF water used is preferably ranges from 50 - 500 wt% based on total weight of the incoming animal skim milk, more preferably ranges from 100 - 350 wt% of the incoming animal skim milk, most preferably ranges from 150 - 250 wt% of the incoming animal skim milk.
- the DF water may be added to the incoming animal skim milk or MFR at once, or the total amount of DF water may be added in several fractions. After each addition of DF water to the incoming animal skim milk or MFR, the diluted liquid composition is subjected to MF.
- MFR compositions were improved using less than 500 wt% DF water, further improved using less than 350 wt% DF water, and even further improved using less than 250 wt% DF water.
- the whey protein content of the MFR generally increases to less preferred levels, which does not improve the fractionation between casein and whey proteins. As such, less whey proteins may permeate the MF membrane and the yield of whey proteins in the MFP decreases, which reduces the effectiveness of the process according to the invention.
- DF water based on total weight of the incoming animal skim milk, more preferably more than 100 wt% of the incoming animal skim milk, most preferably more than 150 wt% of the incoming animal skim milk.
- the above described parameters enable optimisation of the formation of an MF permeate (MFP) and an MF retentate (MFR) which are ideally suited for the preparation of nutritional products for infants, such as infant formulae, follow-on formulae and growing up milks.
- the protein fraction of the MFR originating from step (a) comprises very little whey protein, preferably less than 15 wt%, more preferably less than 10 wt%, based on the weight of the protein fraction in MFR, and is high in casein.
- the protein fraction comprises at least 85 wt% casein, more preferably the protein fraction comprises at least 90 wt% casein.
- the content of total solids in the MFR typically ranges from 5 - 20 wt%, preferably ranges from 7 - 15 wt%, based on total weight of the MFR.
- the amount of whey protein in the MFR originating from step (a) may vary.
- the VCF is carefully chosen to obtain an MFR having a whey protein content below 15 wt% based on weight of the protein fraction.
- the MFR originating from step (a) is preferably subjected to a concentration step (f), resulting in a concentrated MFR.
- Concentration of the MFR originating from step (a) may preferably be accomplished by RO, NF, UF and/or evaporation, more preferably by RO or UF, most preferably by RO.
- the concentrated MFR for example the RO retentate (ROR), the NF retentate (NFR) or the UF retentate (UF2R), is considered to be the MFR originating from step (a), which is subjected to combining in step (c).
- Concentration of the MFR originating from step (a) may be performed by any means known in the art, to obtain a concentrated MFR typically having a total solid content of 12 - 30 wt%, more preferably of 17 - 24 wt%.
- RO, NF or UF of the MFP originating from step (a) is preferably performed using a VCF of 1.5 - 8, more preferably of 1.7 - 3, and at a temperature of 40 - 90 °C, more preferably 45 - 60 °C.
- the inventors found that increasing the temperature as such greatly facilitates the fractionation, as the increasing solid content of the casein enriched MFR induces an increase in viscosity thereof. The viscosity may be reduced by increasing the temperature.
- RO (step (fl)) of the MFR originating from step (a) is especially preferred, as the permeate thereof (ROP) essentially is solvent, in particular water, and nothing else.
- the RO of step (fl) is preferably performed using a VCF of 1.5 - 8, more preferably of 1.7 - 3, and at a temperature of 40 - 90 °C, more preferably 45 - 60 °C.
- the ROP is ideally suitable in this respect, as it basically is pure water, while an NFP may comprise significant amounts of monovalent ions.
- the composition of the ROR is equivalent to the composition of the MFR originating from step (a), only having a increased total solid content. Any RO as known in the art can be used.
- the RO step (fl) of the MFR originating from step (a) is especially preferred in case the process according to the invention is designed such as to obtain a secondary product, which is described further below, as all nutritional material of the MFR originating from step (a) is concentrated in the ROR originating from step (fl). At least part of this ROR is then used in the combining step (c). In one embodiment according to the invention, the remainder is considered to be a surplus stream.
- UF (step (f2)) of the MFR originating from step (a) is preferred as concentration step (f), as the permeate thereof (UF2P) comprises minerals and lactose.
- the UF of step (f2) preferably employs a membrane having a molecular weight cut-off of at most 25 kDa, more preferably at most 10 kDa, and preferably of at least 2.5 kDa, more preferably at least 5 kDa, a VCF of 1.5 - 8, more preferably of 1.7 - 3, and is carried out at a temperature of 40 - 90 °C, more preferably 45 - 60 °C.
- the UF2P obtained from the MFR originating from step (a) is substantially the same as the UFP originating from step (b), and thus both UF2Ps are conveniently combined and further treated together, as described below for the UF2P originating from step (b).
- the UF2P is considered to be a surplus stream.
- the protein composition of the UF2R is equivalent to that of the MFR originating from step (a), and thus can be used as MFR originating from step (a). At least part of the UF2R may then be used in the combining step (c). In one embodiment according to the invention, the remainder is considered to be a surplus stream.
- the UF2R comprises mainly casein, typically at least 75 wt% casein, preferably at least 85 wt% casein, more preferably at least 90 wt% casein, most preferably the UF2R comprises at least 95 wt% casein, based on total dry weight of the UF2R.
- the remainder of the UF2R may include components such as whey proteins, lactose, minerals and the like.
- the part of the UF2R that is not used in the combining step (c) is a valuable product, and may also be referred to as micellar casein.
- the process according to the invention is a closed-loop process, wherein all fractions obtained during the various filtration steps are used in final products. As such, all surplus streams are combined in a secondary product, as is discussed further below.
- concentration step (f) is preferably RO step (fl).
- the MFP originating from step (a) typically has a total solid content of 0.5 - 5 wt%, preferably 1 - 3 wt% based on total weight of the MFP. It is highly preferred to subject the MFP originating from step (a) to a concentration step (g) before subjecting it to the UF of step (b). Concentration of the MFP originating from step (a) preferably is accomplished by RO, F and/or evaporation, most preferably by RO. As such, the concentrated MFP, for example the RO retentate (R02R) or the NF retentate (NFR), is considered to be the MFP originating from step (a), which is subjected to UF in step (b).
- RO RO retentate
- NFR NF retentate
- Concentration of the MFP originating from step (a) may be performed by any means known in the art, to obtain a concentrated MFP typically having a total solid content of 4 - 10 wt%, more preferably 6 - 9 wt%.
- RO or NF of the MFP originating from step (a) is preferably performed using a VCF of 1 - 8, more preferably 2 - 5.
- RO of the MFP originating from step (a) is especially preferred as concentration step (g), as the permeate thereof (R02P) essentially is made up solvent, in particular water, and nothing else.
- the process according to the invention it is one of the preferred embodiments of the process according to the invention to recycle the water originating from concentration steps and use it as DF water in another filtration step of the present process, such as the MF step (a).
- the ROP is ideally suitable in this respect, as it basically is pure water, while the NFP may comprise significant amounts of monovalent ions.
- the composition of the R02R is equivalent to the composition of the MFP originating from step (a), only having an increased total solids content. Any RO as known in the art can be used.
- an MFP originating from step (a) is subjected to an ultrafiltration (UF) step (b), wherein most of the liquid and small solutes end up in the UF permeate (UFP), while the UF retentate (UFR) comprises substantially all whey protein, in a smaller volume.
- Small molecules which permeate through the UF membrane are for example lactose, monovalent and polyvalent ions.
- the incoming stream of the UF step is a liquid composition originating from the MFP.
- the ultrafiltration of step (b) can be carried out with any UF membrane known in the art, including ceramic membranes, tubular and organic spiral wound membranes.
- the UF membrane is an organic spiral wound membrane.
- the UF membrane has a molecular weight cut-off of that enables proteins, preferably whey proteins, to remain in the retentate, and allow small solutes, for example lactose, to permeate through the membrane.
- the UF step (b) preferably is carried out with a membrane having a molecular weight cut-off of at most 25 kDa, more preferably at most 10 kDa, and preferably of at least 2.5 kDa, more preferably at least 5 kDa.
- the UF step (b) preferably operates with a volume concentration factor of 1.5 - 8, preferably 3 - 7, more preferably 3 - 6.
- the UF step (b) is preferably performed below 40 °C, more preferably in the range of 5 °C - 25 °C, even more preferably in the range of 7 °C - 15 °C.
- the above described parameters enable optimisation of the formation of a UF permeate (UFP) and an UF retentate (UFR) originating from the UF step (b), which are ideally suited for the preparation of (base products of) nutritional products for infants, such as infant formulae, follow-on formulae and growing up milks.
- the UFR originating from UF step (b) typically comprises 25 - 50 wt%, preferably 30 - 40 wt% whey proteins based on total dry weight of UFR. The UFR is thus enriched in whey proteins.
- the lactose and mineral (monovalent and polyvalent ions) content of the UFR is reduced when compared to the incoming MFP originating from step (a), as those components permeate through the UF membrane.
- a VCF below 8 preferably below 7, more preferably below 6 retained significant amounts of lactose and minerals in the whey protein enriched UFR to enable efficient preparation of infant formula base products thereof, without exceeding the maximum levels of those components (especially minerals) in the final products.
- Using greater VCFs for the UF of step (b) reduces the lactose and mineral content of the UFR to values below those desired for infant formulae and the like, such that significant supplementation would be needed.
- the lactose-enriched UFP which is obtained when using higher VCF values is high in mineral content, which needs to be lowered before this lactose is suitable for the preparation of infant formula base products.
- Performing the UF of step (b) with smaller VCFs, such as below 1.5 or below 3 does not remove sufficient minerals from the MFR originating from step (a), such that the content of certain minerals in the final infant formula base product would be too high, especially the content of polyvalent ions would be too high.
- this content in the UFR would be too high for infant formulae base product manufacture, this content could be lowered by F as discussed below.
- the UFR of step (b) typically has a total solid content of 5 - 20 wt%, preferably of 10 - 15 wt%. It is highly preferred to subject the UFR to a concentration step (e) before subjecting it to the combining step (c), which makes the process more cost-effective, for example by reducing costs for evaporation and mixing in the final steps.
- the concentration step (e) preferably is RO, NF and/or evaporation, most preferably NF.
- the concentrated UFR for example the RO retentate (ROR) or the NF retentate (NF2R) is considered to be the UFR originating from the UF of step (b), which is subjected to combining in step (c).
- Concentration of the UFR may be performed by any means known in the art, to obtain a concentrated UFR typically having a total solid content of 15 - 35 wt%, more preferably of 20 - 30 wt%.
- concentration step (e) is RO or NF, preferably a VCF of 1 - 6, more preferably of 1.5 - 3 is used.
- NF of the UFR is especially preferred as concentration step (e), as the permeate thereof (NF2P) is reduced in monovalent ions, which are able to permeate the NF membrane.
- the monovalent ion content of the UFR originating from step (b) will be reduced, enabling efficient infant formula base product manufacture.
- NF permeate (NF2P) originating from step (e) typically is a solution of monovalent ions in water, it is not directly suitable as DF water. Therefore it is preferred to remove monovalent ions from the NF2P by RO, as such concentrating the monovalent ions in an R03R and obtaining substantially pure water as R03P.
- F as step (e) employs a spiral wound membrane having a molecular weight cut-off of at most 500 Da, preferably at most 300 Da, and of at least 100 Da, preferably at least 150 Da, and typically operates with a volume concentration factor of 1.5 - 8, preferably 1.8 - 5.
- NF is preferably performed below 40 °C, more preferably from 3 °C - 30 °C, even more preferably from 5 °C - 20 °C.
- the UFR originating from step (b) is further concentrated in whey protein and is reduced in monovalent ion content.
- the remaining part of the NF2P, and optionally the R03R, as obtained in the preferred process of concentration step (e) of the UFR originating from step (b) are considered surplus streams according to the present invention.
- the UFP is enriched in lactose and minerals, and typically has a total solid content of 3 - 10 wt%, preferably of 5 - 7 wt%.
- the lactose present in the UFP is beneficially used to supplement the final infant formula base product, preferably by combining an UFP originating from step (b), preferably a demineralized UFP, with both the MFR originating from step (a) and the UFR originating from step (b), as part of the combining step (c).
- the lactose present in the UFP originating from step (b) may be needed for the preparation of an infant formula base product having the desired lactose content, in one embodiment it is beneficial to split the UFP in a first part that is processed to enable efficient infant formula base product preparation, and in a second part that is processed differently for other nutritional products, preferably for growing-up milks, as will be described further below.
- the UF2P of the preferred option (f2) for concentration step (f) of the MFR originating from step (a) may be combined with the UFP originating from step (b).
- This combining is either performed before the UFP originating from step (b) is split in a first part and a second part, or after the UFP originating from step (b) is split.
- this combining occurs with the second part of the UFP originating from step (b).
- at least part of the UFP originating from step (b) is processed to enable efficient infant formula base product preparation.
- processing typically includes lowering of the mineral content in a demineralization step (d), i.e. lowering of the monovalent ion content and lowering of the polyvalent ion content.
- Such demineralization may take the form of a single step in which significant amounts of both monovalent and polyvalent ions are removed, for example by electrodialysis, or a two-step process in which significant amounts of monovalent and polyvalent ions are removed in two separate steps, for example by ion exchange or salt precipitation for polyvalent ion removal and F for monovalent ion removal.
- the demineralization of step (d) retains all lactose in the UFP originating from step (b), thus in case demineralization of the UFP is part of the process according to the invention, the demineralized UFP is considered the UFP originating from step (b).
- the process according to the invention preferably comprises a step (d), wherein at least part of the UFP originating from step (b) is demineralized, resulting in a demineralized UFP and wherein the demineralized UFP originating from step (d) is subjected to the combining step (c).
- Polyvalent ion removal enables the removal of significant amounts of polyvalent ions.
- the UFP after polyvalent ion removal preferably comprises at least 50 wt% less polyvalent ions, preferably at least 70 wt% less, more preferably at least 80 wt% less, most preferably at least 90 wt% less polyvalent ions, when compared to the incoming UFP originating from step (b).
- Monovalent ion removal causes the removal of significant amounts of monovalent ions.
- the demineralized UFP preferably comprises at least 50 wt% less ions, preferably at least 70 wt% less, more preferably at least 80 wt% less, most preferably at least 90 wt% less ions, when compared to the incoming UF permeate originating from step (b). Removal of polyvalent ions and monovalent ions from the UFP originating from step (b) is especially preferred in the process according to the invention for the preparation of an infant formula base product.
- Polyvalent ion removal and monovalent ion removal which can also be referred to as demineralization step (d) may be accomplished using any technique known in the art, such as electrodialysis, ion exchange, salt precipitation, lactose crystallization, membrane filtration techniques such as nanofiltration, optionally enhanced with diafiltration, or combinations thereof.
- demineralization also includes the crystallization of lactose from the UFP originating from step (b) and simultaneously keeping significant amounts of the polyvalent ions and monovalent ions in solution.
- the obtained crystalline lactose is regarded to be a demineralized UFP in the context of the present invention, as it originates from the UF of step (b) and has significant amounts of the polyvalent ions removed.
- the demineralization step (d) of the UFP originating from step (b) includes salt precipitation, in particular calcium phosphate precipitation, as especially the phosphate content of the incoming animal skim milk is too high for infant formula base products.
- the preferred monovalent ion removal technique is NF.
- at least part of the UFP originating from step (b) is demineralized in step (d) by a combination of salt precipitation and NF.
- the monovalent and polyvalent ion content is lowered simultaneously by filtration over a membrane having a MWCO of 500 - 1000 Da, preferably of 500 - 700 Da, whereby the VCF is typically chosen such that the total solid content of the retentate is in the range of 15 - 30 wt%, preferably in the range of 20 - 25 wt%, most preferably about 22 wt%.
- Such filtration employs slightly larger pores than common NF, which typically has a porosity of at most 300 Da.
- Such larger pores enable the permeation of significant amounts of both monovalent and polyvalent ions, which is not achievable with common NF, and may be accompanied with some lactose permeation.
- step (b) As the total lactose content of the UFP originating from step (b) is generally higher than the desired amount of lactose that is to be combined in the preferred embodiment of step (c), the loss of some lactose in the permeate does not hamper the efficiency of the process according to the invention.
- the demineralization step (d) comprises:
- step (dl) nanofiltration (NF) of at least part of the UFP originating from step (b), resulting in a retentate (NF3R) and a permeate (NF3P);
- step (d2) subjecting the NF3R originating from step (dl) to calcium phosphate salt precipitation;
- step (d3) removing the precipitated salts, resulting in the demineralized UFP.
- demineralization step (d) at least part of the UFP is first subjected to F in step (dl) to remove significant amounts of monovalent ions and to concentrate the lactose and polyvalent ions in the FR.
- the F3P is subsequently subjected to RO, to be able to use the resulting R04P as DF water in another filtration step in the process of the invention, in particular in the MF of step (a).
- the F3R typically has a total solid content of 15 - 30 wt%, preferably of 20 - 25 wt%, most preferably about 22 wt%.
- NF of step (dl) employs a spiral wound membrane having a molecular weight cut-off of at most 500 Da, preferably at most 300 Da, and of at least 100 Da, preferably at least 150 Da, whereby the VCF is typically chosen such that the total solid content of the NF3R is in the range of 15 - 30 wt%, preferably in the range of 20 - 25 wt%, most preferably about 22 wt%.
- NF of step (dl) is preferably performed below 40 °C, more preferably in the range of 3 °C - 30 °C, even more preferably in the range of 5 °C - 20 °C.
- the NF3R is subsequently subjected to calcium phosphate salt precipitation in step (d2), which is preferably accomplished by heating the NF3R to a temperature of 70 °C - 90 °C, preferably of 75 °C - 88 °C, most preferably of 80 °C - 85 °C. At such temperatures, at least part of the calcium phosphate precipitates, which is visible as a white precipitate. Higher temperatures are generally unsuitable, as they may cause undesirable enzymatic browning. Heating may occur by any means known in the art, and is preferably accomplished by steam injection into the NF3R.
- Calcium phosphate precipitation may be enhanced, meaning that a greater fraction of the calcium phosphate precipitates, by increasing the pH of the heated NF3R to a value above 6.5, preferably in the range of 6.8 - 9.0, more preferably in the range of 6.8 - 7.4, and/or by adding other calcium salts such as calcium chloride.
- the NF3R typically has a pH of 6.0 - 6.5, and increasing this to above 6.5, preferably in the range of 6.8 - 9.0, more preferably in the range of 6.8 - 7.4, can be accomplished by addition of a base, preferably an aqueous solution of a metal hydroxide, such as sodium hydroxide, potassium hydroxide and/or calcium hydroxide.
- a concentrated solution sodium hydroxide is used, more preferably a 20 - 35 % (w/v) solution of NaOH in water. Only little of the base solution is needed, as the components that may act as buffer are removed by NF.
- typically about 0.1 - 1 wt% based on the total weight of the NF3R, preferably 0.3 - 0.5 wt% based on the total weight of the NF3R, of a solution of about 30 % (w/v) NaOH in water is used.
- the skilled person is capable to adjust this value for changes in pH of the NF3R, different types of base and different concentrations.
- some additional calcium preferably in the form of calcium chloride, calcium citrate, calcium lactate, calcium hydroxide, or mixtures thereof, preferably calcium chloride, can be added to the heated F3R, which induces the precipitation of more calcium phosphate.
- calcium hydroxide preferably achieves both the pH increase and addition of a calcium salt, but its suitability is slightly hampered by its low solubility.
- a mixture of calcium chloride and sodium hydroxide is added to the F3R to enhance calcium phosphate precipitation.
- the demineralized UFP will have a phosphate content which is further reduced compared to the calcium content.
- step (d3) the precipitate, or more precisely precipitated salts, is removed from the F3R originating from step (d2), resulting in a demineralized UFP.
- This is preferably accomplished by first cooling the heated F3R to a temperature below 25 °C, more preferably in the range of 5 °C - 20 °C, most preferably in the range of 8 °C - 15 °C, before the precipitate is removed from the F3R. Rapidly cooling the F3R is especially preferred, to reduce the chances on undesirable bacterial growth and to minimize the resolubilization of calcium phosphate.
- the precipitate may also be removed from the F3R at an elevated temperature, for example at a temperature above 25 °C.
- Removal of the precipitate in step (d3) is conveniently performed by centrifugal separation, decantation in a settling tank, filtration, for example MF or UF.
- removal step (d3) is performed by filtration, more preferably by UF, which permeates the lactose and soluble minerals and retains the precipitate which predominantly comprises calcium phosphate.
- Any UF membrane as known in the art may be used, although using an UF bed is preferred.
- the VCF of the UF of step (d3) is typically in the range of 5 - 20, preferably in the range of 10 - 15.
- the UF permeate (UF3P) comprises substantially all lactose as originally present in the incoming UFP originating from step (b), which is subjected to the demineralization step (d).
- the UF3P is thus preferably used as the demineralized UFP, in particular as the UPF originating from step (b), in combining step (c).
- this preferred process of demineralization step (d) reduction of the phosphate content of up to 80 wt%, even up to 90 wt%, can be achieved, based on the phosphate content of the UFP obtained in step (b).
- the amount of the UFP needed in that respect may depend on the exact lactose content of the incoming skim milk and the lactose content of each of the MFR originating from step (a) and the UFR originating from step (b), as well as the desired lactose content of the final infant formula base product.
- the skilled person is well aware of the lactose requirements in infant formula base products, and knows how to determine the lactose content in the different liquid compositions, and it is therefore within his or her reach to determine which part of the UFP originating from step (b) is to be subjected to demineralization.
- the process according to the invention is a closed-loop process, wherein all fractions obtained during the various filtration steps are used in final products.
- all surplus streams preferably are combined in a secondary product, as is discussed further below.
- An UFR originating from step (b), an MFR originating from step (a) and preferably an UFP originating from step (b), more preferably a demineralized UFP originating from step (d), are ideally suited to be combined to produce an infant formula base product with the desired protein and lactose content and the desired casein/whey protein weight ratio.
- step (b) whenever the UFR originating from step (b), the MFR originating from step (a) and/or the UFP originating from step (b) undergoes additional processing steps prior to the combining of step (c), such as a concentration step, they are still considered to be the UFR originating from step (b), the MFR originating from step (a) and/or the UFP originating from step (b), respectively, in the context of the present invention.
- step (b) and the MFR originating from step (a), which are subjected to step the combining of step (c), are selected as such, to arrive at a final product having a casein/whey protein weight ratio in the range of 30/70 - 50/50, preferably in the range of 35/65 - 45/55, most preferably in a ratio of about 40/60.
- the amount of the UFP originating from step (b), more preferably of the demineralized UFP originating from step (d), is selected such to arrive at a lactose content in the final product that is desired, or in other words on target, for infant formula base products, thereby taking into account further traces of lactose that may be added during further supplementation, for example from prebiotic supplementation.
- Combining can be performed as wet mixing or as dry mixing or even a combination of both.
- the combining occurs as wet mixing, wherein liquid compositions are mixed in the appropriate amounts.
- These liquid compositions may undergo further additional processing steps prior to mixing.
- additional processing steps may include, preferably are limited to, concentrating the liquid stream, preferably increasing the total solids content, for example via evaporation or partial evaporation or filtration techniques such as nanofiltration or reverse osmosis, heat-treatment, such as for example pasteurization, such as HTST, ESL or UHT or sterilization, for example dry heat or moist heat sterilization and/or supplementation of additional water or other components.
- the liquid composition is dried to a powder.
- combining step (c) is performed as dry mixing, wherein each liquid composition individually is dried prior to mixing.
- combining step (c) occurs by mixing at least one liquid composition and at least one dry, or dried composition. Drying of a liquid composition, either after or prior to mixing, may be accomplished by any means known in the art, e.g. spray drying, (fluidized) bed drying, drum drying, freeze drying, roller drying, etc. In an especially preferred embodiment, drying is accomplished using spray drying, optionally preceded by partial evaporation of the liquid.
- the mixing is performed using liquid compositions in the appropriate amounts, thus preferably by wet mixing, after which the mixture is dried, preferably spray-dried.
- the mixture is dried, preferably spray-dried.
- Conventional processes for preparing infant formula base products contain more drying steps, such as drying of a casein containing composition, drying of a whey protein containing composition, drying of lactose , in particular crystallized lactose. Drying, such as spray-drying, is a costly procedure, which is typically performed at high temperatures, such as above 150 °C or even above 180 °C. Reducing the amount of (spray-)drying steps to just one greatly improves the efficiency of the process.
- the process according to the invention does not comprise a (spray-)drying step prior to combining step (c).
- additional process steps such as partial evaporation may be performed prior to combining or in between combining and (spray-)drying, according to this preferred embodiment of the invention.
- Such optional further processing steps include, preferably are limited to, concentrating the liquid stream (i.e. increasing the total solid content, e.g. via (partial) evaporation), heat- treatment, for example pasteurization, such as HTST, ESL or UHT, or sterilization, for example dry heat or moist heat sterilization and/or supplementation of additional water or other components.
- an infant formula base product preferably in the form of a powder.
- an infant formula base product comprises all proteinaceous material in the desired content for the manufacture of infant formulae and the like.
- other components such as minerals, vitamins, lactose, prebiotics are also present in their desired contents, more preferably at least the minerals are present in the desired contents.
- the desired content is determined with respect to the protein content in the infant formula base product, as the total dry matter of the infant formula is likely to change, for example by fat addition. It is highly advantageous that upon combining in step (c), the content of the essential components other than casein and whey protein are on or below target.
- the content of at least one of phosphorus, calcium, magnesium, sodium, potassium and chloride is on target, more preferably the content of at least two of phosphorus, calcium, magnesium, sodium, potassium and chloride are on target, even more preferably the content of at least three of phosphorus, calcium, magnesium, sodium, potassium and chloride are on target, even more preferably the content of at least four of phosphorus, calcium, magnesium, sodium, potassium and chloride are on target, most preferably the content of at least five of phosphorus, calcium, magnesium, sodium, potassium and chloride are on target.
- the content of one or more minerals is below target, fortification with that particular mineral may be needed.
- the final product is supplemented with any ingredient which is below target.
- the amounts of ions such as phosphorus, sodium, potassium, chlorine and magnesium are advantageously within the desired range, when the UFR originating from step (b) is combined with the MFR originating from step (a) in the appropriate ratio to obtain a composition having the required casein/whey protein weight ratio.
- the infant formula base product originating from step (c) is further processed into an infant formula, a follow-on formula or a growing-up milk, preferably into an infant formula, by methods known in the art.
- the fat content may be below target for an infant formula, as the process operates most efficiently when the fat content of the incoming animal skim milk is minimal.
- the final product may be supplemented with fat, which enables the supplementation of a specifically designed fat component, which is ideally suitable for infant nutrition.
- supplementation is performed with prebiotics, vitamins, probiotics, etc, as known in the art.
- Further processing of the infant formula base product preferably comprises one or more of, more preferably all of, concentrating, wet and/or dry blending of one of the above mentioned ingredients, preferably of minerals, vitamins and fat, homogenizing, heat- treating, drying. Supplementation and/or fortification of particular ingredients can be either prior to, during or after combining step (c) and/or optionally prior to or after a drying step.
- the process preferably operates with 1 - 2000 tonne animal skim milk, more preferably 10 - 200 tonne, most preferably 50 - 100 tonne animal skim milk incoming per hour.
- the process preferably operates with an output of 0.1 - 1000 tonne, more preferably 0.5 - 100 tonne, most preferably 2 - 40 tonne UFR obtained directly from step (b) per hour.
- the process according to the invention provides sufficient removal of polyvalent ions and preferably monovalent ions, by virtue of the microfiltration step (a) and the ultrafiltration step (b), preferably combined with demineralization of the UFP originating therefrom, so that all minerals are at or below their desired or required level for infant nutrition.
- all minerals are at or below their desired or required level for infant nutrition.
- the content of a certain mineral is below the desired level, preferably that mineral is added to be on target, as for example according to EU directive 91/321/EEC or EU directive 2006/141/EC or US Food and Drug Administration 21 CFR Ch 1 part 107.
- the process according to the invention may afford residual water at several points, in particular as ROP obtained in for example the concentration of any of the MFR and MFP originating from step (a) and the UFR and UFP originating from step (b), but optionally also from the drying step.
- this residual water optionally after further purification by e.g. additional RO step(s), is recycled in the process according to the invention, preferably as diafiltration water to dilute or reconstitute the incoming animal skim milk.
- the process according to the invention is a closed-loop process, wherein all surplus streams are combined and processed into a secondary product.
- the process according to the present invention may afford two distinct products, one of which is the infant formula base product.
- the secondary product is preferably a nutritional product suitable for feeding infants from 6 - 36 months of age, preferably for feeding infants from 12 - 36 months of age, or an ingredient for a nutritional product suitable for feeding infants from 6 - 36 months of age, preferably for feeding infants from 12 - 36 months of age, most preferably the secondary product is a growing-up milk.
- Surplus streams obtained by the present process include part of the MFR originating from step (a) and part of the UFP originating from step (b), and may include NFPs or RORs obtained in concentration steps. Those surplus streams are preferably combined and used for the manufacture of the secondary product.
- the major proteinaceous material of the secondary product is casein from the MFR originating from step (a).
- Casein from the MFR originating from step (a) is a nutritionally acceptable protein source for infants from 6 - 36 months of age.
- the major carbohydrate source of the secondary product is lactose from the UFP originating from step (b).
- Any FP or ROR originating from the process according to the invention is typically rich in beneficial minerals for infants from 6 - 36 months of age.
- the surplus streams as defined in the process of the invention are combined into a casein-rich composition, which typically comprises 50-60 wt% protein, based on dry weight of the composition of which casein preferably constitutes at least 80 wt%, for example 85 - 95 wt%, based on total protein and the carbohydrate content is typically at least 30 wt%, for example 30 - 40 wt%, based on dry weight of the composition while ash, as a measure for the mineral content, preferably constitute from 7 - 14 wt% based on dry weight of the composition.
- a casein-rich composition typically comprises 50-60 wt% protein, based on dry weight of the composition of which casein preferably constitutes at least 80 wt%, for example 85 - 95 wt%, based on total protein and the carbohydrate content is typically at least 30 wt%, for example 30 - 40 wt%, based on dry weight of the composition while ash, as a measure for the mineral content, preferably constitute from 7
- the combined surplus streams thus represents a valuable starting point for manufacturing secondary nutritional products according to the invention and thus in one aspect the present invention concerns a casein rich composition
- a casein rich composition comprising i) 40 - 50 g casein per 100 g dry weight, preferably 43 - 48 g casein per 100 g dry weight,
- casein rich composition further comprises
- NPN non-protein-nitrogen
- the casein rich composition comprises
- This casein-rich composition is ideally suited as ingredient for nutritional products for infants from 6 - 36 months of age, preferably for infants from 12 - 36 months of age, such as growing-up milks. Additional ingredients are preferably added to the combined surplus streams to prepare the secondary product, such as whey protein, further lactose or other carbohydrates, fat, vitamins, minerals, prebiotics, probiotics and other beneficial ingredients for infants from 6 - 36 months of age, preferably for infants from 12 - 36 months of age as known in the art. Supplementation with minerals may not be required, or may not be required to a great extent, as the surplus streams contain significant amounts of minerals, especially in case one or more UFP and/or ROR is obtained as surplus stream.
- the protein fraction of the secondary product comprises preferably at least 50 wt% casein, more preferably at least 55 wt% casein, even more preferably at least 60 wt% casein, even more preferably at least 65 wt% casein most preferably at least 70 wt% casein, based on total weight of protein in the secondary product, wherein the source of casein is MFR originating form step (a) of the process acoording to the invention..
- the protein fraction of the secondary product comprises preferably at least 80 wt% casein, more preferably at least 85 wt% casein, more preferably at least 90 wt% casein, even more preferably at least 95 wt% casein, most preferably at least 99 wt% casein, based on total weight of protein in the secondary product, wherein the source of casein is MFR originating form step (a) of the process according to the invention.
- the source of casein is MFR originating form step (a) of the process according to the invention.
- the protein from a different source compsises whey protein.
- protein from a different source is added in such an amount to arrive at a casein/whey protein weight ratio of 50/50 - 100/0.
- the process according to the invention includes using part of the MFR originating from step (a) as protein source in the manufacture of a secondary nutritional product, wherein the secondary nutritional product comprises at most 50 wt% of protein from a different source, preferably at most 45 wt%, preferably at most 40 wt%, more preferably at most 35 wt% of protein from a different source. Also, according to a preferred embodiment, the process according to the invention includes using part of the MFR originating from step (a) as protein source in the manufacture of a secondary nutritional product, wherein the secondary nutritional product comprises at most 20 wt%, preferably at most 10 wt% of protein from a different source.
- the secondary nutritional product is suitable for feeding infants form 6 - 36 months of age, perferably for feeding infants form 12 - 36 months of age, preferably for feeding toddlers, more preferably the secondary nutritional product is a growing-up milk.
- the MFR originating from step (a) that is used in this embodiment is MFR that is a surplus stream of MF step (a), or in other words the MFR originating from step (a) that is used in this embodiment, is MFR that is not used in step (c).
- the manufacture of a secondary nutritional product comprises a combining step (h), wherein a part of the MFR originating from step (a), preferably a surplus stream of microfiltration step (a), is combined with a part of the UFP originating from step (b).
- the UFP originating from step (b) that is used in this embodiment is UFP that is a surplus stream of UF step (b), or in other words the UFP originating from step (b) that is used in this embodiment, is the second part of the UFP originating from step (b), which is not used in step (d).
- the combining step (h) further comprises combining with an FP or an ROR, as obtained in any of optional steps (dl), (e), (fl) and (g).
- an FP or an ROR as obtained in any of optional steps (dl), (e), (fl) and (g).
- all FPs or RORs, as obtained in optional steps (dl), (e), (fl) and (g) are combined in step (h), for the manufacture of the secondary nutritional product.
- the combined surplus streams, prior to the addition of any further ingredient which is not directly obtained from the incoming skim milk are subjected to a drying step, which may be accomplished by any means known in the art, e.g. spray drying, bed drying, fluidized-bed drying, drum drying, freeze drying, roller drying, etc.
- drying is accomplished by spray drying, optionally preceded by partial evaporation of the liquid.
- the present invention also relates to a nutritional product suitable for feeding infants form 6 - 36 months of age, preferably toddlers, preferably a growing-up milk, wherein the nutritional product comprises at most 10 wt% of protein from a different source than the protein comprised in the MFR originating from step (a).
- the nutritional product comprises at most 10 wt% of protein from a different source than the protein comprised in the MFR originating from step (a).
- a protein source different from MFR originating from step (a) is added or even no protein from a different source than MFR originating from step (a) is added.
- the protein from a different source compsises whey protein.
- protein from a different source is added in such an amount to arrive at a casein/whey protein weight ratio of 90/10 - 100/0.
- a further aspect of the present invention is a process for the manufacture of a nutritional product suitable for feeding infants from 6 - 36 months of age, comprising:
- step (ii) optionally reverse osmosis (RO) of an MFR originating from step (i), resulting in a retentate (R02R) and a permeate (R02P);
- RO reverse osmosis
- Step (iii) combining at least part of an MFR originating from step (i) or an R02R originating from (ii) as protein source with one or more additional ingredients, wherein the nutritional product comprises less than 50 wt% of protein from a different source than the protein comprised in the MFR originating from step (i).
- Step (i) is preferably performed identically to step (a).
- Step (ii) is preferably performed identically to step (fl).
- Step (iii) can be performed as wet mixing or as dry mixing or even a combination of both.
- the nutritional product of combining step (iii) comprises less than 45 wt%, more preferably less than 40 wt%, even more preferably less than 35 wt% or even less than 30 wt% of protein from a different source than the protein comprised in the MFR originating from step (i). In one embodiment, the nutritional product of combining step (iii) comprises less than 20 wt%, more preferably less than 15 wt%, even more preferably less than 10 wt%, of protein from a different source than the protein comprised in the MFR originating from step (i).
- the protein from a different source preferably comprises whey protein.
- the combining occurs as wet mixing, wherein liquid compositions are mixed in the appropriate amounts.
- Such liquid compositions may undergo further additional processing steps prior to mixing.
- additional processing steps may include, preferably are limited to, concentrating the liquid stream, preferably increasing the total solid content, for example via evaporation or partial evaporation or filtration techniques such as nanofiltration or reverse osmosis, heat-treatment, such as for example pasteurization, such as HTST, ESL or UHT or sterilization, for example dry heat or moist heat sterilization and/or supplementation of additional water or other components.
- the one or more additional ingredients that are subjected to the combining step (iii) are preferably chosen from whey protein, lactose, sucrose or other carbohydrates, fat, vitamins, minerals, an UFP originating from step (iv), prebiotics, probiotics and other beneficial ingredients for infants from 6 - 36 months of age as known in the art.
- the process according to the present aspect of the invention further comprises:
- step (iv) ultrafiltration (UF) of an MFP originating from step (i) over a membrane having a molecular weight cut-off of at most 25 kDa and operating with a volume concentration factor of 1.5 - 8, resulting in a retentate (UFR) and a permeate (UFP),
- step (iii) comprises combining with at least part of an UFP originating from step (iv).
- Step (iv) is preferably performed identically to step (b).
- the combining step (iii) further comprises combining with one or more surplus streams obtained from the process of the preparation of an infant formula base product from animal skim milk, such as FPs or RORs or both.
- the combined MFR originating from step (i) or R02R originating from (ii) and UFP originating from step (iv), and any other surplus stream obtained by the process according to the invention, prior to the addition of any additional ingredient that is not directly obtained from the incoming skim milk, are subjected to a drying step, which may be accomplished by any means known in the art, e.g. spray drying, bed drying, fluidized bed drying, drum drying, freeze drying, roller drying, etc. In an especially preferred embodiment, drying is accomplished by spray drying, optionally preceded by partial evaporation of the liquid.
- the process according to the present aspect of the invention is for the preparation of a nutritional product suitable for feeding infants from 6 - 36 months of age, preferably toddlers, preferably for the preparation of a growing-up milk, wherein the nutritional product comprises less than 50 wt% of protein from a different source than from an MFR of animal skim milk, preferably less than 45 wt%, more preferably less than 40 wt%, even more preferably less than 35 wt% even more preferably less than 30 wt% of protein from a different source than from an MFR of animal skim milk or in one embodiment, the nutritional product comprises less than 20 wt%, more preferably less than 15 wt%, even more preferably less than 10 wt%, of protein from a different source than from an MFR of animal skim milk.
- This process is a marked improvement over prior art processes for the preparation of nutritional products suitable for feeding toddlers, which have a high casein content, for example less than 10 wt% of the protein can be obtained from another source than from an MFR of animal skim milk.
- the present process greatly saves on drying of the toddlers nutritional product, by virtue of the inclusion of different ingredients which are all obtained from the same animal skim milk, such as the UFP originating from step (iv) and any FP and/or ROR obtained as surplus stream in the manufacture of an infant formula base product from animal skim milk.
- a further aspect of the invention is the infant formula base product obtainable by the process according to the invention, as described herein.
- a further aspect of the invention is the nutritional product suitable for feeding infants from 6 - 36 months of age, preferably toddlers, obtainable by the process according to the invention, as described herein.
- the calcium, sodium, potassium, and magnesium contents were determined via atomic absorption spectrometric method (ISO 8070/ IDF 119).
- the phosphorus content was determined via molecular absorption spectrometry (ISO 9874/ IDF 42).
- the protein content (N * 6.38) was determined with FT001 / IDF 20-3, the casein content with IDF29-1/ISO 17997- 1 :2004, the whey protein content (NCN, non-casein nitrogen * 6.38) with FT003, and the non-protein nitrogen (as N) with FT419 IDF20 Part 4.
- Example 1 Effect of diafiltration (DF) on microfiltration (MF) of animal skim milk
- DF diafiltration
- MF microfiltration
- Trial duration was 24 hrs producing a retentate enriched in micellar casein and a permeate enriched in whey protein.
- the mass balance of the feed, retentate and permeate streams and compositional analyses thereof are outlined in tables 2 and 3 respectively.
- the MFR had been enriched in protein to a level of > 75 wt%, based on total dry weight (contains about 90 wt% casein based on total protein), and a total solids content of at least 10 wt%, based on total weight of the MFR. Lactose levels decreased to a level of -15 wt%, based on total dry weight and mineral levels expressed as ash remained at 7.4 wt%, based on total dry weight.
- the MFP stream produced during MF was much lower in protein; -12.3 wt%, based on total dry weight, , which was shown to be primarily ⁇ - casein (data not shown).
- Lactose levels were very high at -75 wt%, based on total dry weight, while the mineral content expressed as ash was at -8.3 wt%, based on total dry weight.
- Monovalent ion levels for Na, K, CI were high in the permeate stream, and polyvalent ion levels for Ca and P were high in the retentate stream, while magnesium was retained in both streams at similar levels.
- Filtration duration was - 16 hrs and 115 kg dry matter of a RO retentate enriched in whey protein, lactose and minerals was collected.
- compositional analyses of the ROR is equivalent to the values presented in table 3 for the MFP on a dry matter basis as the RO essentially removed only water, which in itself is suitable for recycling and use as diafiltration water for the incoming skim milk feed to step a.
- Example 4 - UF of an MFP ROR, with concomitant concentration of the UFR by NF The ROR of example 3 (2085 kg) was subjected to ultrafiltration (UF), using a Model F pilot filtration plant (GEA), equipped with two 4" 3838 spiral wound organic UF membranes in series (Synder Filtration), having a molecular weight cut off (MWCO) of 10 kDa.
- Compositional analyses of the UF retentate and permeate streams are outlined in table 4.
- the UFR stream comprised a protein content - 39 wt%, based on total dry weight, and had a total solids content of - 8.0 wt%, based on total weight of the UFR stream. Ash levels were reduced compared to the incoming MFP stream, as well as the lactose content, essentially the UFR stream comprised all true protein.
- the UFP stream was enriched in ash and lactose compared to both the MFP and the UFR and while the UFP comprised no true protein it did contain significant quantities of non-protein-nitrogen.
- NPN g/lOOg dry matter 0.30 0.43 0.20
- the demineralization of the UFP is achievable through one or a combination of the following steps, removal of monovalent ions using a NF membrane having a MWCO of 150-500 Da, pH or temperature induced precipitation of calcium/magnesium salts as citrate and phosphate, or removal of monovalent and polyvalent ions by strong/weak anionic/cationic ion exchange resins or removal of monovalent and polyvalent ions by electrodialysis.
- composition of the UFP and the desirable demineralised UFP according to the invention are outlined in table 5, the demineralised UFP has reduced levels of nonprotein nitrogen, ash and minerals compared to the incoming UFP feed, with increased levels of lactose expressed on a DM basis. Table 5. Compositional analysis of feed UFP and desired demineralization level for the demineralized UFP
- the MFR and NFR streams are combined in an infant formula base product having a casein/whey protein weight ratio of 40/60.
- a target infant formula base product as described in table 5 35.5 kg of MFR and 108 kg of NFR liquid streams were blended to meet the required protein content and casein to whey ratio of an infant formula.
- the deficit in lactose content for an infant formula derived by blending the MFR and NFR streams is compensated for by blending the aforementioned streams with 158 kg of the demineralised UFP described in table 5.
- prebiotics and a fat blend are added.
- infant formula base product produced closely matches the macronutritional requirements of the target formulation, and while some mineral levels fall below the target level, particularly calcium and chloride these can be easily increased after the combining step using salts thereof.
- table 7 lists amino acids of an infant milk formula produced according to the invention expressed in % of human milk at a protein content of 2g/100 kcal. It is clear that levels of cystine and tryptophan are increased compared to traditionally produced infant milk formula, while levels of threonine are reduced as no cheese whey derivatives are used according to the invention.
- This stream is suitable for use as a protein source (primarily casein) in follow-on (FO) and growing-up milk (GUM) formulations whereby the macronutrional composition may be balanced by blending the CPC with sweet whey derivatives such as lactose, whey protein concentrate and demineralised whey, preferably along with prebiotics, fat blends and other micronutrients.
- sweet whey derivatives such as lactose, whey protein concentrate and demineralised whey, preferably along with prebiotics, fat blends and other micronutrients.
- Table 8 Composition of a casein protein concentrate produced by blending all surplus milk materials according to the invention
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20205463.1A EP3837985A3 (en) | 2013-09-19 | 2014-09-19 | Improved process for the humanization of animal skim milk |
EP14777920.1A EP3046420B1 (en) | 2013-09-19 | 2014-09-19 | Improved process for the humanization of animal skim milk |
RU2016114740A RU2732833C2 (en) | 2013-09-19 | 2014-09-19 | Method for humanisation of skimmed milk of animals |
PL14777920T PL3046420T3 (en) | 2013-09-19 | 2014-09-19 | Improved process for the humanization of animal skim milk |
NZ717998A NZ717998A (en) | 2013-09-19 | 2014-09-19 | Improved process for the humanization of animal skim milk |
DK14777920.1T DK3046420T3 (en) | 2013-09-19 | 2014-09-19 | Improved approach to humanization of animal skimmed milk |
CN201480063087.5A CN105848486A (en) | 2013-09-19 | 2014-09-19 | Improved process for the humanization of animal skim milk |
AU2014321908A AU2014321908B2 (en) | 2013-09-19 | 2014-09-19 | Improved process for the humanization of animal skim milk |
BR112016005949A BR112016005949A2 (en) | 2013-09-19 | 2014-09-19 | process for preparing a product based on infant formula, process for manufacturing a nutritional product suitable for feeding babies of 6? 36 months old, nutritional composition for babies of 6? 36 months obtainable by the process, and casein rich composition |
US15/022,815 US10674739B2 (en) | 2013-09-19 | 2014-09-19 | Method for processing animal skim milk |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NLPCT/NL2013/050671 | 2013-09-19 | ||
PCT/NL2013/050671 WO2015041515A1 (en) | 2013-09-19 | 2013-09-19 | Improved process for the humanization of animal skim milk |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015041529A2 true WO2015041529A2 (en) | 2015-03-26 |
WO2015041529A3 WO2015041529A3 (en) | 2015-05-28 |
Family
ID=49304287
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2013/050671 WO2015041515A1 (en) | 2013-09-19 | 2013-09-19 | Improved process for the humanization of animal skim milk |
PCT/NL2014/050643 WO2015041529A2 (en) | 2013-09-19 | 2014-09-19 | Improved process for the humanization of animal skim milk |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2013/050671 WO2015041515A1 (en) | 2013-09-19 | 2013-09-19 | Improved process for the humanization of animal skim milk |
Country Status (10)
Country | Link |
---|---|
US (1) | US10674739B2 (en) |
EP (2) | EP3046420B1 (en) |
CN (1) | CN105848486A (en) |
AU (1) | AU2014321908B2 (en) |
BR (1) | BR112016005949A2 (en) |
DK (1) | DK3046420T3 (en) |
NZ (1) | NZ717998A (en) |
PL (1) | PL3046420T3 (en) |
RU (1) | RU2732833C2 (en) |
WO (2) | WO2015041515A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018029222A1 (en) | 2016-08-08 | 2018-02-15 | Compagnie Gervais Danone | Process for producing infant formula products and acidic dairy products from milk |
WO2018028765A1 (en) * | 2016-08-08 | 2018-02-15 | Compagnie Gervais Danone | Process for producing infant formula products and dairy products |
WO2019160402A1 (en) | 2018-02-15 | 2019-08-22 | N.V. Nutricia | Native whey protein for reducing allergy |
WO2019160416A1 (en) | 2018-02-15 | 2019-08-22 | N.V. Nutricia | Native whey protein for reducing allergy |
WO2020159372A1 (en) | 2019-02-01 | 2020-08-06 | N.V. Nutricia | Native whey protein for treating and/or preventing intestinal infection |
WO2020159373A1 (en) | 2019-02-01 | 2020-08-06 | N.V. Nutricia | Native whey protein for improving intestinal maturation |
WO2022089732A1 (en) | 2020-10-27 | 2022-05-05 | N.V. Nutricia | Native whey protein composition for improving gastro-intestinal tolerance |
RU2793288C2 (en) * | 2016-08-08 | 2023-03-31 | Компани Жервэ Данон | Method of producing baby food and fermented milk products from milk |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2825058B1 (en) * | 2012-03-12 | 2020-02-12 | N.V. Nutricia | Process for the humanization of animal skim milk and products obtained thereby |
WO2014163485A1 (en) * | 2013-04-03 | 2014-10-09 | N.V. Nutricia | Process and system for preparing dry milk formulae |
MX2018016041A (en) * | 2016-06-21 | 2019-09-19 | Arla Foods Amba | Process for production of improved nutritional products containing milk protein and milk saccharides, and products obtained by the process. |
SG10202100843TA (en) | 2016-07-28 | 2021-03-30 | Fonterra Cooperative Group Ltd | Dairy product and process |
MX2019012078A (en) * | 2017-05-08 | 2020-01-13 | Evoqua Water Tech Llc | Water treatment of sodic, high salinity, or high sodium waters for agricultural applications. |
EP3542634B1 (en) * | 2018-03-21 | 2021-06-30 | DMK Deutsches Milchkontor GmbH | Milk protein concentrates with reduced ash content |
EP3817566A1 (en) * | 2018-07-03 | 2021-05-12 | Fairlife, LLC | Production and separation of milk fractions with forward osmosis |
WO2020251350A1 (en) * | 2019-06-13 | 2020-12-17 | N.V. Nutricia | Process for manufacturing an infant formula product with hydrolysed protein |
CN117481198A (en) * | 2024-01-02 | 2024-02-02 | 内蒙古蒙牛乳业(集团)股份有限公司 | Membrane separation recombination method for core nutritional ingredients of infant milk product and application of membrane separation recombination method |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169666A (en) | 1991-11-14 | 1992-12-08 | The United States Of America As Represented By The Secretary Of Agriculture | Preparation of simulated human milk protein by low temperature microfiltration |
WO1996008155A1 (en) | 1994-09-16 | 1996-03-21 | New Zealand Dairy Board | Physical separation of casein and whey proteins |
US5503865A (en) | 1992-12-28 | 1996-04-02 | Nestec S.A. | Processes for the preparation of concentrated milk products |
US5683984A (en) | 1994-02-25 | 1997-11-04 | Nestec S.A. | Enteral tube feeding composition with a native micellar casein protein component |
WO2001022837A1 (en) | 1999-09-29 | 2001-04-05 | Societe Des Produits Nestle S.A. | Composition comprising casein protein and whey protein |
EP1133238A1 (en) | 1998-11-24 | 2001-09-19 | Societe Des Produits Nestle S.A. | Method for preparing a protein composition and an infant formula containing same |
WO2008127104A1 (en) | 2007-04-16 | 2008-10-23 | Friesland Brands B.V. | Functional serum protein product for use in infant food and therapeutic compositions and methods for the preparation thereof |
WO2009059266A1 (en) | 2007-11-02 | 2009-05-07 | Select Milk Producers, Inc. | Methods for casein production |
EP2096941B1 (en) | 2006-12-15 | 2012-02-01 | Nestec S.A. | Nutritional composition for infants |
CN102630803A (en) | 2012-05-15 | 2012-08-15 | 东北农业大学 | Humanized milk protein and preparation method thereof |
WO2013009182A1 (en) | 2011-07-13 | 2013-01-17 | Friesland Brands B.V. | Dairy based compositions with low lps |
WO2013068653A2 (en) | 2011-11-11 | 2013-05-16 | Valio Ltd | Method for producing a milk product |
WO2013068563A2 (en) | 2011-11-11 | 2013-05-16 | Ucb Pharma S.A. | Antibody molecules having specificity for human ox40 |
WO2013137714A1 (en) | 2012-03-12 | 2013-09-19 | N.V. Nutricia | Process for the humanization of animal skim milk and products obtained thereby |
EP2413952B1 (en) | 2009-04-03 | 2016-03-23 | Nestec S.A. | Improvement in promotion of healthy catch-up growth |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2631785A1 (en) | 1988-05-27 | 1989-12-01 | Agronomique Inst Nat Rech | METHOD FOR FRACTIONING HUMAN MILK PROTEINS, DRIVING PRODUCTION, IN PARTICULAR LACTOFERRIN AND (ALPHA) -LACTALBUMIN, AND PRODUCTS OBTAINED |
WO1994006306A1 (en) | 1992-09-22 | 1994-03-31 | New Zealand Dairy Board | A process for producing beta-casein enriched products |
US5670196A (en) | 1995-04-12 | 1997-09-23 | Galagen Inc. | Method for microfiltration of milk or colostral whey |
US6485762B1 (en) | 1999-07-26 | 2002-11-26 | Cornell Research Foundation, Inc. | Microfiltration of skim milk for cheese making and whey proteins |
US20070166447A1 (en) | 2002-08-27 | 2007-07-19 | Select Milk Producers, Inc. | Dairy compositions and method of making |
US20050181095A1 (en) * | 2004-02-18 | 2005-08-18 | Dominion Nutrition, Inc. | Concentrated-protein food product and process |
JP4761356B2 (en) * | 2005-08-29 | 2011-08-31 | 株式会社明治 | Milk material with excellent flavor and physical properties and method for producing the same |
US8889208B2 (en) * | 2005-11-09 | 2014-11-18 | Wisconsin Alumni Research Foundation | Purification of beta casein from milk |
WO2009113845A1 (en) | 2008-03-12 | 2009-09-17 | N.V. Nutricia | High protein liquid enteral nutritional composition |
CN101909468A (en) | 2007-12-05 | 2010-12-08 | 荷兰纽迪希亚公司 | Liquid enteral nutritional composition with a low specific protein volume |
US20110097442A1 (en) * | 2009-10-28 | 2011-04-28 | Valio Oy | Whey protein product and a method for its preparation |
CA2778360A1 (en) * | 2009-10-28 | 2011-05-05 | Valio Ltd. | Whey protein product and a method for its preparation |
NO20100391A1 (en) | 2010-03-17 | 2011-02-28 | Tine Sa | Membrane filtration and membrane filtration assembly |
NL2006662C2 (en) | 2011-04-26 | 2012-10-29 | Friesland Brands Bv | Method of making a milk protein composition. |
US20130064923A1 (en) * | 2011-09-13 | 2013-03-14 | Agropur Cooperative | Liquid Milk Beverage For Toddlers |
ES2650164T3 (en) * | 2012-06-15 | 2018-01-17 | Arla Foods Amba | Dairy products with increased water binding |
EP2839749B1 (en) * | 2013-08-18 | 2019-01-02 | DMK Deutsches Milchkontor GmbH | Ground mass for curd cheese with improved taste properties III |
-
2013
- 2013-09-19 WO PCT/NL2013/050671 patent/WO2015041515A1/en active Application Filing
-
2014
- 2014-09-19 EP EP14777920.1A patent/EP3046420B1/en active Active
- 2014-09-19 PL PL14777920T patent/PL3046420T3/en unknown
- 2014-09-19 AU AU2014321908A patent/AU2014321908B2/en active Active
- 2014-09-19 NZ NZ717998A patent/NZ717998A/en unknown
- 2014-09-19 RU RU2016114740A patent/RU2732833C2/en not_active Application Discontinuation
- 2014-09-19 US US15/022,815 patent/US10674739B2/en active Active
- 2014-09-19 BR BR112016005949A patent/BR112016005949A2/en not_active Application Discontinuation
- 2014-09-19 CN CN201480063087.5A patent/CN105848486A/en active Pending
- 2014-09-19 DK DK14777920.1T patent/DK3046420T3/en active
- 2014-09-19 WO PCT/NL2014/050643 patent/WO2015041529A2/en active Application Filing
- 2014-09-19 EP EP20205463.1A patent/EP3837985A3/en active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169666A (en) | 1991-11-14 | 1992-12-08 | The United States Of America As Represented By The Secretary Of Agriculture | Preparation of simulated human milk protein by low temperature microfiltration |
US5503865A (en) | 1992-12-28 | 1996-04-02 | Nestec S.A. | Processes for the preparation of concentrated milk products |
US5683984A (en) | 1994-02-25 | 1997-11-04 | Nestec S.A. | Enteral tube feeding composition with a native micellar casein protein component |
WO1996008155A1 (en) | 1994-09-16 | 1996-03-21 | New Zealand Dairy Board | Physical separation of casein and whey proteins |
EP1133238A1 (en) | 1998-11-24 | 2001-09-19 | Societe Des Produits Nestle S.A. | Method for preparing a protein composition and an infant formula containing same |
NZ511562A (en) | 1998-11-24 | 2003-10-31 | Nestle Sa | Method for preparing a protein composition and an infant formula containing same |
WO2001022837A1 (en) | 1999-09-29 | 2001-04-05 | Societe Des Produits Nestle S.A. | Composition comprising casein protein and whey protein |
EP2096941B1 (en) | 2006-12-15 | 2012-02-01 | Nestec S.A. | Nutritional composition for infants |
WO2008127104A1 (en) | 2007-04-16 | 2008-10-23 | Friesland Brands B.V. | Functional serum protein product for use in infant food and therapeutic compositions and methods for the preparation thereof |
WO2009059266A1 (en) | 2007-11-02 | 2009-05-07 | Select Milk Producers, Inc. | Methods for casein production |
EP2413952B1 (en) | 2009-04-03 | 2016-03-23 | Nestec S.A. | Improvement in promotion of healthy catch-up growth |
WO2013009182A1 (en) | 2011-07-13 | 2013-01-17 | Friesland Brands B.V. | Dairy based compositions with low lps |
WO2013068653A2 (en) | 2011-11-11 | 2013-05-16 | Valio Ltd | Method for producing a milk product |
WO2013068563A2 (en) | 2011-11-11 | 2013-05-16 | Ucb Pharma S.A. | Antibody molecules having specificity for human ox40 |
WO2013137714A1 (en) | 2012-03-12 | 2013-09-19 | N.V. Nutricia | Process for the humanization of animal skim milk and products obtained thereby |
CN102630803A (en) | 2012-05-15 | 2012-08-15 | 东北农业大学 | Humanized milk protein and preparation method thereof |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11109605B2 (en) | 2016-08-08 | 2021-09-07 | Compagnie Gervals Danone | Process for producing infant formula products and dairy products |
RU2793288C2 (en) * | 2016-08-08 | 2023-03-31 | Компани Жервэ Данон | Method of producing baby food and fermented milk products from milk |
AU2017311557B2 (en) * | 2016-08-08 | 2022-02-10 | Compagnie Gervais Danone | Process for producing infant formula products and dairy products |
WO2018028764A1 (en) * | 2016-08-08 | 2018-02-15 | Compagnie Gervais Danone | Process for producing infant formula products and acidic dairy products |
CN109788772A (en) * | 2016-08-08 | 2019-05-21 | 达能日尔维公司 | By the method for cream production infant formula product and acidic dairy prod |
CN109788771A (en) * | 2016-08-08 | 2019-05-21 | 达能日尔维公司 | The method for producing infant formula product and dairy products |
AU2017311560B2 (en) * | 2016-08-08 | 2021-09-16 | Compagnie Gervais Danone | Process for producing infant formula products and acidic dairy products from milk |
US11116233B2 (en) | 2016-08-08 | 2021-09-14 | Compagnie Gervais Danone | Process for producing infant formula products and acidic dairy products from milk |
WO2018029216A1 (en) | 2016-08-08 | 2018-02-15 | Compagnie Gervais Danone | Process for producing infant formula products and dairy products |
WO2018028765A1 (en) * | 2016-08-08 | 2018-02-15 | Compagnie Gervais Danone | Process for producing infant formula products and dairy products |
WO2018029222A1 (en) | 2016-08-08 | 2018-02-15 | Compagnie Gervais Danone | Process for producing infant formula products and acidic dairy products from milk |
WO2019160416A1 (en) | 2018-02-15 | 2019-08-22 | N.V. Nutricia | Native whey protein for reducing allergy |
WO2019160402A1 (en) | 2018-02-15 | 2019-08-22 | N.V. Nutricia | Native whey protein for reducing allergy |
WO2020159373A1 (en) | 2019-02-01 | 2020-08-06 | N.V. Nutricia | Native whey protein for improving intestinal maturation |
WO2020159356A1 (en) | 2019-02-01 | 2020-08-06 | N.V. Nutricia | Native whey protein for improving intestinal maturation |
WO2020159372A1 (en) | 2019-02-01 | 2020-08-06 | N.V. Nutricia | Native whey protein for treating and/or preventing intestinal infection |
WO2020159357A1 (en) | 2019-02-01 | 2020-08-06 | N.V. Nutricia | Native whey protein for treating and/or preventing intestinal infection |
WO2022089732A1 (en) | 2020-10-27 | 2022-05-05 | N.V. Nutricia | Native whey protein composition for improving gastro-intestinal tolerance |
WO2022090269A1 (en) | 2020-10-27 | 2022-05-05 | N.V. Nutricia | Native whey protein composition for improving gastro-intestinal tolerance |
Also Published As
Publication number | Publication date |
---|---|
PL3046420T3 (en) | 2021-04-19 |
RU2016114740A (en) | 2017-10-24 |
DK3046420T3 (en) | 2020-11-30 |
EP3046420A2 (en) | 2016-07-27 |
AU2014321908A1 (en) | 2016-04-21 |
EP3046420B1 (en) | 2020-11-04 |
WO2015041515A1 (en) | 2015-03-26 |
US20160205960A1 (en) | 2016-07-21 |
RU2732833C2 (en) | 2020-09-23 |
RU2016114740A3 (en) | 2018-09-05 |
EP3837985A2 (en) | 2021-06-23 |
NZ717998A (en) | 2021-12-24 |
AU2014321908B2 (en) | 2018-07-26 |
WO2015041529A3 (en) | 2015-05-28 |
US10674739B2 (en) | 2020-06-09 |
CN105848486A (en) | 2016-08-10 |
EP3837985A3 (en) | 2021-09-29 |
BR112016005949A2 (en) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014321908B2 (en) | Improved process for the humanization of animal skim milk | |
EP2825058B1 (en) | Process for the humanization of animal skim milk and products obtained thereby | |
EP2986153B1 (en) | Process and system for preparing dry milk formulae | |
EP2988604B1 (en) | Process and system for preparing dry milk formulae | |
ES2782473T3 (en) | Method to produce a starting formula base | |
AU2017311557B2 (en) | Process for producing infant formula products and dairy products | |
WO2018028764A1 (en) | Process for producing infant formula products and acidic dairy products | |
NZ712768B2 (en) | Process and system for preparing dry milk formulae | |
NZ712773B2 (en) | Process and system for preparing dry milk formulae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14777920 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 15022815 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201601851 Country of ref document: ID |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016005949 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2014777920 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014777920 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016114740 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014321908 Country of ref document: AU Date of ref document: 20140919 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016005949 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160317 |